Every now and again something intriguing comes along, which generates a flurry of interest from our…
Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?
The devil is in the finer details...
An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.
What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?
A new emerging IO target of interest caught out attention, now what?
A novel epigenetic target may have far-reaching outcomes for cancer patients
The ups and downs of CAR-T cell therapy development continues apace
What can we learn from the recent announcements for lurbinectedin in 2L SCLC and the CDK4/6 inhibitors in adjuvant HR+HER2- early breast cancer.
Highlights from several solid tumour trials in both early and late stage disease.
A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer
Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20
Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2
A look at the revised schedule and timelines for upcoming Spring cancer conference season
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space
Our latest analysis of the ever evolving NSCLC landscape following BMS’s announcement on CheckMate-227
Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?
Analysis and predictions of two oncology phase 3 readouts coming soon...
A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials
Cell therapy is a very broad church - here's an interesting approach to keep an eye on
Update on BCMA, SLAMF7 and other targets in multiple myeloma
It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some…
A look at some of the issues underlying IO-IO combos and whether they can help us assess if these trials will succeed - or not.
A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout
A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC
A look at the FDA briefing docs on Puma's neratinib
We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?
BSB Reader Mailbag on TRK/ROS1/ALK inhibitors
Latest BSB reader Q&A looks at 5 questions from subscribers
Reader Q&A on women's cancers relating to HER2, PARP and TNBC...
A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape
Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16
July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
This month's Biotech Strategy Blog mail bag.
Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...
